References
- Ameri A. (1998). The effects of Aconitum alkaloids on the central nervous system. Prog Neurobiol 56:211–235.
- Ando Y, Fuse E, Figg WD. (2002). Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964–1973.
- Bachmann KA, Ghosh R. (2001). The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2:299–314.
- Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M. (2004). Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res 21:2095–2104.
- Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57.
- Eagling VA, Tjia JF, Back DJ. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107–114.
- FDA. (2006). Guidance for Industry: Drug Metablism/Drug Interaction Studies in the Drug Development Process: Studies In vitro.
- Hikino H, Murayama M. (1985). Mechanism of the antinociceptive action of mesaconitine: participation of brain stem and lumbar enlargement. Br J Pharmacol 85:575–580.
- Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ. (2003). Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos 31:924–931.
- Isono T, Oyama T, Asami A, Suzuki Y, Hayakawa Y, Ikeda Y, Noguchi M, Omiya Y. (1994). The analgesic mechanism of processed Aconiti tuber: the involvement of descending inhibitory system. Am J Chin Med 22:83–94.
- Kobayashi K, Urashima K, Shimada N, Chiba K. (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833–836.
- Li AP, Kaminski DL, Rasmussen A. (1995). Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1–8.
- Liu W, Tang L, Ye L, Cai Z, Xia B, Zhang J, Hu M, Liu Z. (2010). Species and gender differences affect the metabolism of emodin via glucuronidation. AAPS J 12:424–436.
- Mitamura M, Boussery K, Horie S, Murayama T, Van de Voorde J. (2002a). Vasorelaxing effect of mesaconitine, an alkaloid from Aconitum japonicum, on rat small gastric artery: possible involvement of endothelium-derived hyperpolarizing factor. Jpn J Pharmacol 89:380–387.
- Mitamura M, Horie S, Sakaguchi M, Someya A, Tsuchiya S, Van de Voorde J, Murayama T, Watanabe K. (2002b). Mesaconitine-induced relaxation in rat aorta: involvement of Ca2+ influx and nitric-oxide synthase in the endothelium. Eur J Pharmacol 436:217–225.
- Ogura J, Mitamura M, Someya A, Shimamura K, Takayama H, Aimi N, Horie S, Murayama T. (2004). Mesaconitine-induced relaxation in rat aorta: role of Na+/Ca2+ exchangers in endothelial cells. Eur J Pharmacol 483:139–146.
- Ohno Y. (1998). The experimental approach to the murder case of aconite poisoning. J Tox Rev 17:1–11.
- Omura T. (1999). Forty years of cytochrome P450. Biochem Biophys Res Commun 266:690–698.
- Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, Zanovello P, Floreani M. (2005). Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 11:1608–1617.
- Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. (1997). Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18:227–240.
- Suzuki Y, Oyama T, Ishige A, Isono T, Asami A, Ikeda Y, Noguchi M, Omiya Y. (1994). Antinociceptive mechanism of the aconitine alkaloids mesaconitine and benzoylmesaconine. Planta Med 60:391–394.
- Wacher VJ, Wu CY, Benet LZ. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134.
- Wang Y, Wang S, Liu Y, Yan L, Dou G, Gao Y. (2006). Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine. J Chromatogr B Analyt Technol Biomed Life Sci 844:292–300.
- Wilkinson GR. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221.
- Xie FM, Wang HC, Shu HL, Li JH, Jiang JR, Chang JP, Hsieh YY. (1990). Separation and characterization of the metabolic products of lappaconitine in rat urine by high-performance liquid chromatography. J Chromatogr 526:109–118.
- Zhang HG, Sun Y, Duan MY, Chen YJ, Zhong DF, Zhang HQ. (2005). Separation and identification of Aconitum alkaloids and their metabolites in human urine. Toxicon 46:500–506.